{"id":310629,"date":"2019-12-19T22:00:35","date_gmt":"2019-12-20T06:00:35","guid":{"rendered":"https:\/\/nai500.com\/blog\/2019\/12\/metabomed\/"},"modified":"2019-12-19T23:33:45","modified_gmt":"2019-12-20T07:33:45","slug":"metabome-%e5%ae%8c%e6%88%90-1250-%e4%b8%87%e7%be%8e%e5%85%83%e7%9a%84%e8%9e%8d%e8%b5%84%e5%8a%a0%e9%80%9f%e5%80%99%e9%80%89%e8%8d%af%e7%89%a9%e8%bf%9b%e5%85%a5%e4%b8%b4%e5%ba%8a","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hans\/blog\/2019\/12\/metabome-%e5%ae%8c%e6%88%90-1250-%e4%b8%87%e7%be%8e%e5%85%83%e7%9a%84%e8%9e%8d%e8%b5%84%e5%8a%a0%e9%80%9f%e5%80%99%e9%80%89%e8%8d%af%e7%89%a9%e8%bf%9b%e5%85%a5%e4%b8%b4%e5%ba%8a\/","title":{"rendered":"Metabomed\u5b8c\u62101250\u4e07\u7f8e\u5143\u7684\u878d\u8d44\uff0c\u52a0\u901f\u5019\u9009\u836f\u7269\u8fdb\u5165\u4e34\u5e8a"},"content":{"rendered":"<p>\u9886\u5148\u7684\u764c\u75c7\u4ee3\u8c22\u516c\u53f8Metabomed\u5b8c\u6210\u4e861250\u4e07\u7f8e\u5143\u7684\u878d\u8d44\uff0c\u4f7f\u8fc4\u4eca\u4e3a\u6b62\u7b79\u96c6\u7684\u8d44\u91d1\u603b\u989d\u8fbe\u52303000\u4e07\u7f8e\u5143\u3002\u8be5\u516c\u53f8\u5ba3\u5e03\u65e8\u5728\u52a0\u901f\u9776\u5411\u4f9d\u8d56\u4e59\u9178\u916f\u4ee3\u8c22\u7684\u764c\u75c7\u4e2d\u7684\u4e59\u9170\u8f85\u9176A\u77ed\u94fe\u5408\u91762\u9176\uff08ACSS2\uff09\u6291\u5236\u4f5c\u7528\u7684\u4e34\u5e8a\u5019\u9009\u836f\u7269\u3002<\/p>\n<p>\u8be5\u8f6e\u878d\u8d44\u7531Yonjin Venture\u7275\u5934\uff0c\u6240\u6709\u73b0\u6709\u6295\u8d44\u8005\u53c2\u4e0e\u5176\u4e2d\uff1aM Ventures\uff0cPfizer Ventures\uff0cPontifax Venture Fund\uff0cBoehringer Ingelheim Venture Fund\u548cArkin Bio Ventures\u3002\u8be5\u8f6e\u878d\u8d44\u7684\u6536\u76ca\u5c06\u7528\u4e8e\u57282020\u5e74\u5e95\u4e4b\u524d\u5c06Metabomed\u7684ACSS2\u8ba1\u5212\u4e34\u5e8a\u5019\u9009\u836f\u7269\u8f6c\u4e3a\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\uff0c\u5e76\u52a0\u5f3a\u5176\u5185\u90e8\u6e20\u9053\u4ee5\u8fdb\u4e00\u6b65\u5f00\u53d1MetaboMed\u7684\u5176\u4ed6\u8ba1\u5212\u7684\u5148\u5bfc\u5316\u5408\u7269\u3002<\/p>\n<p>Metabomed\u9996\u5e2d\u6267\u884c\u5b98\u517c\u8054\u5408\u521b\u59cb\u4ebaSimone Botti\u535a\u58eb\u8bf4\uff1a\u201c\u6211\u4eec\u5f88\u8363\u5e78\u5c06Yonjin Venture\u5217\u5165Metabomed\u7684\u9876\u7ea7\u6295\u8d44\u8005\u540d\u5355\uff0c\u6211\u4eec\u5bf9\u73b0\u6709\u80a1\u4e1c\u7684\u4fe1\u4efb\u6295\u7968\u611f\u5230\u9ad8\u5174\u3002\u6211\u4eec\u5bf9\u6240\u6709\u8ba1\u5212\u7684\u8fdb\u5c55\u611f\u5230\u5174\u594b\uff0c\u5c24\u5176\u662f\u6709\u673a\u4f1a\u5c06\u4e00\u6d41\u7684ACSS2\u6291\u5236\u5242\u63a8\u5411\u66f4\u9760\u8fd1\u8bca\u6240\u7684\u673a\u4f1a\u3002\u6211\u4eec\u5e0c\u671b\u80fd\u591f\u5f88\u5feb\u8868\u660e\uff0c\u9488\u5bf9\u764c\u75c7\u7684\u5408\u6210\u81f4\u6b7b\u6027\u4ee3\u8c22\u8106\u5f31\u6027\u7684\u65b9\u6cd5\u5c06\u5728\u4e34\u5e8a\u4e0a\u5f97\u5230\u8bc1\u660e\uff0c\u4f8b\u5982\u7528\u4f5c\u6cbb\u7597\u4e09\u9634\u6027\u4e73\u817a\u764c\uff0c\u76ee\u524d\u7684\u6cbb\u7597\u6807\u51c6\u4e0d\u80fd\u4e3a\u8bb8\u591a\u60a3\u8005\u63d0\u4f9b\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6cd5\u3002\u201d<\/p>\n<p>\u8be5\u516c\u53f8\u8463\u4e8b\u957fDavid Aviezer\u6559\u6388\u8865\u5145\u8bf4\uff1a\u201c\u901a\u8fc7\u8fd9\u4e00\u8f6e\u878d\u8d44\uff0cMetabomed\u51ed\u501f\u5176\u9886\u5148\u7684\u5316\u5408\u7269\u8fc5\u901f\u8fdb\u5165\u4e34\u5e8a\u8bd5\u9a8c\u9636\u6bb5\uff0c\u5e76\u8fdb\u4e00\u6b65\u52a0\u5f3a\u4e86\u5176\u6709\u524d\u9014\u7684\u4ea7\u54c1\u7ebf\u3002\u201d<\/p>\n<p>Yonjin Venture\u8463\u4e8b\u603b\u7ecf\u7406Daguang Wang\u8868\u793a\uff1a\u201c\u6211\u4eec\u5f88\u9ad8\u5174\u6210\u4e3a\u764c\u75c7\u4ee3\u8c22\u9886\u57df\u9886\u5bfc\u8005Metabomed\u7684\u4e00\u90e8\u5206\u3002\u6211\u4eec\u671f\u5f85\u7740\u4e0e\u516c\u53f8\u53ca\u5176\u8463\u4e8b\u4f1a\u5408\u4f5c\u3002\u201d\u3002<\/p>\n<p>Metabomed\u662f\u4e00\u5bb6\u5728\u764c\u75c7\u4ee3\u8c22\u9886\u57df\u7684\u836f\u7269\u5f00\u53d1\u516c\u53f8\u3002\u901a\u8fc7\u5176\u4e13\u6709\u6280\u672f\uff0cMetabomed\u53ef\u4ee5\u8bc6\u522b\u5728\u764c\u75c7\u4e2d\u72ec\u7279\u51fa\u73b0\u4e14\u5bf9\u5176\u751f\u957f\u81f3\u5173\u91cd\u8981\u7684\u4ee3\u8c22\u9014\u5f84\u3002\u8fd9\u4e9b\u53d1\u73b0\u88ab\u7528\u4e8e\u5f00\u53d1\u4e13\u95e8\u9488\u5bf9\u91cd\u65b0\u7f16\u7a0b\u7684\u764c\u7ec6\u80de\u4ee3\u8c22\u4ee5\u963b\u6b62\u5176\u751f\u957f\u7684\u5c0f\u5206\u5b50\u3002\u7531\u4e8e\u8fd9\u4e9b\u5206\u5b50\u6291\u5236\u4e86\u764c\u7ec6\u80de\u7279\u6709\u7684\u53d1\u6563\u9014\u5f84\uff0c\u56e0\u6b64\u8fd9\u4e9b\u7597\u6cd5\u4e0d\u4f1a\u635f\u5bb3\u5065\u5eb7\u7684\u5468\u56f4\u7ec4\u7ec7\u3002<\/p>\n<p>Yonjin Venture LLC\uff0c\u4f4d\u4e8e\u9a6c\u8428\u8bf8\u585e\u5dde\u5251\u6865\u5e02\uff0c\u662f\u4e2d\u56fd\u4e0a\u6d77\u6c38\u8fdb\u96c6\u56e2\u7684\u98ce\u9669\u6295\u8d44\u90e8\u95e8\u3002Yonjin Venture LLC\u4e13\u4e1a\u4ece\u4e8b\u5317\u7f8e\u548c\u6b27\u6d32\u7684\u751f\u547d\u79d1\u5b66\u6295\u8d44\u3002<\/p>\n<p>\u82f1\u6587\u6765\u6e90\uff1aBiospace<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Metabomed, a leading cancer metabolism company completed a financing of $12.5 million bringing the total raised to date to $30 million. The company announced that it has declared a clinical candidate for its first-in-class program targeting the inhibition of the AcetylCoA Short chain Synthase 2 enzyme (ACSS2) in cancers dependent on acetate metabolism.<\/p>\n","protected":false},"author":9,"featured_media":310624,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[193],"tags":[820,455,459],"class_list":["post-310629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized_zh-hans","tag-820","tag-455","tag-459","sectors-life-science-zh-hans","locations-china-zh-hans","locations-us-zh-hans"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/310629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=310629"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/310629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media\/310624"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=310629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=310629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=310629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}